Clariane €92 million reserved capital increase and €237 million rights offering
We advised Clariane on its refinancing transactions
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
IDEAYA Biosciences $302.5 million equity offering
The common stock is listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $230 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
InflaRx $75 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Tempus AI $410 million IPO
The stock is listed on the Nasdaq Global Select Market
ProKidney $140 million follow-on offerings
We advised ProKidney on the offering
Royalty Pharma $1.5 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering
Medtronic €3 billion notes offering
The notes are due 2029, 2036, 2043 and 2053
Elevance Health $2.6 billion senior notes offering
The investment-grade notes are due 2029, 2034 and 2054
Merck €3.4 billion notes offering
The investment-grade notes offering consists of four tranches